Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of Phenylketonuria

Molecular Genetics and Metabolism

Volumn 104, Issue 3, 2011, Pages 249-254

  Sarkissian, Christineh N ^a   Kang, Tse Siang ^b,c   Gámez, Alejandra ^b,d   Scriver, Charles R ^a   Stevens, Raymond C ^b  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Hyperphenylalaninemia; Oral enzyme substitution therapy; Phenylalanine ammonia lyase; Phenylketonuria

Indexed keywords

ALGINIC ACID; CHITOSAN; DEXTRAN SULFATE; PHENYLALANINE; PHENYLALANINE AMMONIA LYASE;

ADJUVANT THERAPY; AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET THERAPY; DRUG CONJUGATION; DRUG EFFICACY; DRUG FORMULATION; ENZYME SUBSTITUTION THERAPY; ENZYME THERAPY; FEMALE; MALE; MOUSE; NONHUMAN; PHENYLKETONURIA; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ALGINATES; ANABAENA VARIABILIS; ANALYSIS OF VARIANCE; ANIMALS; BASIDIOMYCOTA; CHITOSAN; DEXTRAN SULFATE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCURONIC ACID; HEXURONIC ACIDS; MICE; NANOPARTICLES; PHENYLALANINE; PHENYLALANINE AMMONIA-LYASE; PHENYLKETONURIAS; RECOMBINANT PROTEINS;

MUS;

EID: 82455199281     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.06.016     Document Type: Article

References (40)

1. Scriver C.R. The PAH gene, phenylketonuria, and a paradigm shift. Hum. Mutat. 2007, 28:831-845.
2. Donlon J., Levy H.L., Scriver C.R. Hyperphenylalanine: Phenylalanine Hydroxylase Deficiency 2010, McGraw-Hill/Medical Publishing Division, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, B. Childs, K.W. Kinzler (Eds.).
3. Cockburn F., Clark B.J. Recommendations for protein and amino acid intake in phenylketonuric patients. Eur. J. Pediatr. 1996, 155(Suppl. 1):S125-129.
4. Fisch R.O. Comments on diet and compliance in phenylketonuria. Eur. J. Pediatr. 2000, 159(Suppl. 2):S142-144.
5. Walter J.H., White F.J., Hall S.K., MacDonald A., Rylance G., Boneh A., Francis D.E., Shortland G.J., Schmidt M., Vail A. How practical are recommendations for dietary control in phenylketonuria?. Lancet 2002, 360:55-57.
6. Erlandsen H., Pey A.L., Gamez A., Perez B., Desviat L.R., Aguado C., Koch R., Surendran S., Tyring S., Matalon R., Scriver C.R., Ugarte M., Martinez A., Stevens R.C. Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:16903-16908.
7. Muntau A.C., Roschinger W., Habich M., Demmelmair H., Hoffmann B., Sommerhoff C.P., Roscher A.A. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N. Engl. J. Med. 2002, 347:2122-2132.
8. Burton B.K., Grange D.K., Milanowski A., Vockley G., Feillet F., Crombez E.A., Abadie V., Harding C.O., Cederbaum S., Dobbelaere D., Smith A., Dorenbaum A. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J. Inherit. Metab. Dis. 2007, 30:700-707.
9. Levy H.L., Milanowski A., Chakrapani A., Cleary M., Lee P., Trefz F.K., Whitley C.B., Feillet F., Feigenbaum A.S., Bebchuk J.D., Christ-Schmidt H., Dorenbaum A. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 2007, 370:504-510.
10. Gamez A., Wang L., Straub M., Patch M.G., Stevens R.C. Toward PKU enzyme replacement therapy: PEGylation with activity retention for three forms of recombinant phenylalanine hydroxylase. Mol. Ther. 2004, 9:124-129.
11. Sarkissian C.N., Gamez A. Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now?. Mol. Genet. Metab. 2005, 86(Suppl. 1):S22-26.
12. Sarkissian C.N., Gamez A., Wang L., Charbonneau M., Fitzpatrick P., Lemontt J.F., Zhao B., Vellard M., Bell S.M., Henschell C., Lambert A., Tsuruda L., Stevens R.C., Scriver C.R. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:20894-20899.
13. Sarkissian C.N., Shao Z., Blain F., Peevers R., Su H., Heft R., Chang T.M., Scriver C.R. A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:2339-2344.
14. Hoskins J.A., Gray J. Phenylalanine ammonia lyase in the management of phenylketonuria: the relationship between ingested cinnamate and urinary hippurate in humans. Res. Commun. Chem. Pathol. Pharmacol. 1982, 35:275-282.
15. Wang L., Gamez A., Archer H., Abola E.E., Sarkissian C.N., Fitzpatrick P., Wendt D., Zhang Y., Vellard M., Bliesath J., Bell S.M., Lemontt J.F., Scriver C.R., Stevens R.C. Structural and biochemical characterization of the therapeutic Anabaena variabilis phenylalanine ammonia lyase. J. Mol. Biol. 2008, 380:623-635.
16. Bourget L., Chang T.M. Artificial cell-microencapsulated phenylalanine ammonia-lyase. Appl. Biochem. Biotechnol. 1984, 10:57-59.
17. Ambrus C.M., Ambrus J.L., Horvath C., Pedersen H., Sharma S., Kant C., Mirand E., Guthrie R., Paul T. Phenylalanine depletion for the management of phenylketonuria: use of enzyme reactors with immobilized enzymes. Science (New York, N.Y) 1978, 201:837-839.
18. Kang T.S., Wang L., Sarkissian C.N., Gamez A., Scriver C.R., Stevens R.C. Converting an injectable protein therapeutic into an oral form: phenylalanine ammonia lyase for phenylketonuria. Mol. Genet. Metab. 2010, 99:4-9.
19. Frankel A.D., Pabo C.O. Cellular uptake of the TAT protein from human immunodeficiency virus. Cell 1988, 55:1189-1193.
20. Green M., Loewenstein P.M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 1988, 55:1179-1188.
21. Ho A., Schwarze S.R., Mermelstein S.J., Waksman G., Dowdy S.F. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer res. 2001, 61:474-477.
22. Sarmento B., Ribeiro A., Veiga F., Ferreira D., Neufeld R. Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromolecules 2007, 8:3054-3060.
23. Bhopatkar D., Anal A.K., Stevens W.F. Ionotropic alginate beads for controlled intestinal protein delivery: effect of chitosan and barium counter-ions on entrapment and release. J. Microencapsul. 2005, 22:91-100.
24. Morch Y.A., Donati I., Strand B.L., Skjak-Braek G. Effect of Ca2+, Ba2+, and Sr2+ on alginate microbeads. Biomacromolecules 2006, 7:1471-1480.
25. Heng P.W., Chan L.W., Wong T.W. Formation of alginate microspheres produced using emulsification technique. J. Microencapsul. 2003, 20:401-413.
26. Shedlovsky A., McDonald J.D., Symula D., Dove W.F. Mouse models of human phenylketonuria. Genetics 1993, 134:1205-1210.
27. McDonald J.D., Charlton C.K. Characterization of mutations at the mouse phenylalanine hydroxylase locus. Genomics 1997, 39:402-405.
28. Armstrong M.D., Tyler F.H. Studies on phenylketonuria. I. Restricted phenylalanine intake in phenylketonuria. J. Clin. Invest. 1955, 34:565-580.
29. Bickel H., Gerrard J., Hickmans E.M. The influence of phenylalanine intake on the chemistry and behaviour of a phenyl-ketonuric child. Acta Paediatr. 1954, 43:64-77.
30. Woolf L.I., Griffiths R., Moncrieff A. Treatment of phenylketonuria with a diet low in phenylalanine. Br. Med. J. 1955, 1:57-64.
31. Guthrie R., Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963, 32:338-343.
32. Snapper I., Yu T.F., Chiang Y.T. Cinnamic acid metabolism in man. Proc. Soc. Exp. Biol. Med. 1940, 44:30-34.
33. Hoskins J.A., Holliday S.B., Greenway A.M. The metabolism of cinnamic acid by healthy and phenylketonuric adults: a kinetic study. Biomed. Mass Spectrom. 1984, 11:296-300.
34. Gamez A., Wang L., Sarkissian C.N., Wendt D., Fitzpatrick P., Lemontt J.F., Scriver C.R., Stevens R.C. Structure-based epitope and PEGylation sites mapping of phenylalanine ammonia-lyase for enzyme substitution treatment of phenylketonuria. Mol. Genet. Metab. 2007, 91:325-334.
35. Wang L., Gamez A., Sarkissian C.N., Straub M., Patch M.G., Han G.W., Striepeke S., Fitzpatrick P., Scriver C.R., Stevens R.C. Structure-based chemical modification strategy for enzyme replacement treatment of phenylketonuria. Mol. Genet. Metab. 2005, 86:134-140.
36. Gamez A., Sarkissian C.N., Wang L., Kim W., Straub M., Patch M.G., Chen L., Striepeke S., Fitzpatrick P., Lemontt J.F., O'Neill C., Scriver C.R., Stevens R.C. Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria. Mol. Ther. 2005, 11:986-989.
37. Fritz R.R., Hodgins D.S., Abell C.W. Phenylalanine ammonia-lyase. Induction and purification from yeast and clearance in mammals. J. Biol. Chem. 1976, 251:4646-4650.
38. Chang T.M., Bourget L., Lister C. A new theory of enterorecirculation of amino acids and its use for depleting unwanted amino acids using oral enzyme-artificial cells, as in removing phenylalanine in phenylketonuria. Artif. Cells Blood Substit. Immobi.l Biotechnol. 1995, 23:1-21.
39. Ascenzi P., Bocedi A., Bolognesi M., Spallarossa A., Coletta M., De Cristofaro R., Menegatti E. The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): a milestone protein. Curr. Protein Pept. Sci. 2003, 4:231-251.
40. Bayer Temporarily Suspends Global Trasylol® Marketing http://www.trasylol.com/Trasylol_11_05_07.pdf.